EUVIMEDEUVIMED entdecken
Fallbericht

Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion–Positive High-Grade Glioma

Jillian Simoneau, Patricia Robertson, Karin Muraszko, Cormac O Maher, Hugh Garton, Rebecca Calvert, Carl Koschmann, Santhosh A Upadhyaya, Rajen Mody, Noah Brown, Chandan Kumar-Sinha, Hemant Parmar und 2 weitere

Journal of the National Comprehensive Cancer Network · 2024

DOI: 10.6004/jnccn.2024.7045 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024. Verfasst von Jillian Simoneau und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Michigan, Michigan Medicine, Ann Arbor, MI. Hauptthemen laut MEDLINE: Pyrazoles, Glioma, Receptor, trkB, Pyrimidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tissue-agnostic, molecularly targeted therapies are becoming increasingly common in cancer treatment. The molecular drivers of some classes and subclasses of tumors are rapidly being uncovered in an era of deep tumor sequencing occurring at the time of diagnosis. When and how targeted therapies should fit within up-front cytotoxic chemotherapy and radiation paradigms is yet to be determined, because many of them have been studied in single-arm studies in patients with relapsed or refractory cancer. Infant high-grade gliomas (HGGs) are biologically and clinically distinct from older child and adult HGGs, and are divided into 3 molecular subgroups. Group 1 infant HGGs are driven by receptor tyrosine kinase fusions, most commonly harboring an ALK , ROS1 , NTRK , or MET fusion. Both larotrectinib and entrectinib are tropomyosin receptor kinase inhibitors with tissue-agnostic approvals for the treatment of patients with solid tumors harboring an NTRK fusion. This report discusses an 11-month-old female who presented with infantile spasms, found to have an unresectable, NTRK fusion–positive infant HGG. Larotrectinib was prescribed when the NTRK fusion was identified at diagnosis, and without additional intervention to date, the patient has continued with stable disease for >3 years. The only adverse event experienced was grade 1 aspartate transaminase and alanine transaminase elevations. The patient has a normal neurologic examination, is developing age-appropriately in all domains (gross motor, fine motor, cognitive, language, and social-emotional). She is no longer on antiseizure medications. To our knowledge, this is the first report of a patient with an infantile HGG receiving targeted therapy as first-line treatment with prolonged stable disease. A prospective study of larotrectinib in patients with newly diagnosed infant HGG is ongoing, and will hopefully help answer questions about durability of response, the need for additional therapies, and long-term toxicities seen with TRK inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesGliomaReceptor, trkBPyrimidinesProtein Kinase InhibitorsHumansFemaleInfantOncogene Proteins, FusionBrain NeoplasmsNeoplasm GradingTreatment OutcomeMembrane Glycoproteins

Substanzen

larotrectinibPyrazolesReceptor, trkBPyrimidinestropomyosin-related kinase-B, humanProtein Kinase InhibitorsOncogene Proteins, FusionMembrane Glycoproteins

Autor:innen und Institutionen

  • Department of Pediatrics, University of Michigan, Michigan Medicine, Ann Arbor, MI.
  • Department of Neurosurgery, University of Michigan, Michigan Medicine, Ann Arbor, MI.
  • Department of Neurosurgery, Stanford University, Stanford, CA.
  • Department of Pathology, University of Michigan, Michigan Medicine, Ann Arbor, MI.
  • Department of Radiology, University of Michigan, Michigan Medicine, Ann Arbor, MI.

Zitieren

APA

Simoneau, J., Robertson, P., Muraszko, K., Maher, C. O., Garton, H., Calvert, R., Koschmann, C., Upadhyaya, S. A., Mody, R., Brown, N., Kumar-Sinha, C., Parmar, H., Camelo-Piragua, S., & Franson, A. T. (2024). Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion–Positive High-Grade Glioma. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2024.7045

Vancouver

Simoneau J, Robertson P, Muraszko K, Maher CO, Garton H, Calvert R, et al. Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion–Positive High-Grade Glioma. Journal of the National Comprehensive Cancer Network. 2024. doi:10.6004/jnccn.2024.7045

BibTeX
@article{Simoneau2024,
  author = {Simoneau, Jillian and Robertson, Patricia and Muraszko, Karin and Maher, Cormac O and Garton, Hugh and Calvert, Rebecca and Koschmann, Carl and Upadhyaya, Santhosh A and Mody, Rajen and Brown, Noah and Kumar-Sinha, Chandan and Parmar, Hemant and Camelo-Piragua, Sandra and Franson, Andrea T},
  title = {Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion–Positive High-Grade Glioma},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2024},
  doi = {10.6004/jnccn.2024.7045}
}
Kostenlos starten →